OM-89
ApprovedSmall molecule
OM-89 is one of 51 small molecule programs targeting Chronic Prostatitis. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Medrol
PfizerPhase 3
Merrem
BB. Braun Medical Inc.
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Piperacillin/tazobactam
PfizerPhase 3
Prulifloxacin
Merck & Co.Phase 3
Amoxicillin/clavulanate Potassium
Johnson & JohnsonPhase 3
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
OM-89
AAJU Pharm Co., Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Prostatitis1 trial
Urinary Tract Infection1 trial
Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder
Recruiting·—·Phase 3·NCT06588010·110 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OM-89. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAJU Pharm Co., Ltd.